Seth Ettenberg, President and CEO of BlueRock Therapeutics:
“Parkinson’s disease is incredibly complex, with symptoms often varying hour to hour through the course of the day. New tools and approaches are needed to ease the reporting burden on patients in trials and to measure and assess disease progression more effectively. We are excited to be working with the pioneering team at Emerald Innovations to harness the power of their digital health technologies to collect an unbiased, objective and continuous measure of disease progression that will help us develop more effective therapies.”